BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32816910)

  • 1.
    Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
    Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
    Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.
    Rhodes SD; He Y; Smith A; Jiang L; Lu Q; Mund J; Li X; Bessler W; Qian S; Dyer W; Sandusky GE; Horvai AE; Armstrong AE; Clapp DW
    Hum Mol Genet; 2019 Aug; 28(16):2752-2762. PubMed ID: 31091306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities.
    Kresbach C; Dottermusch M; Eckhardt A; Ristow I; Paplomatas P; Altendorf L; Wefers AK; Bockmayr M; Belakhoua S; Tran I; Pohl L; Neyazi S; Bode H; Farschtschi S; Well L; Friedrich RE; Reuss D; Snuderl M; Hagel C; Mautner VF; Schüller U
    Neuro Oncol; 2023 Sep; 25(9):1644-1655. PubMed ID: 36866403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
    Carroll SL
    Am J Pathol; 2016 Mar; 186(3):464-77. PubMed ID: 26740486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
    Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
    Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
    Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.
    Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C
    Elife; 2022 Mar; 11():. PubMed ID: 35244537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.
    Miettinen MM; Antonescu CR; Fletcher CDM; Kim A; Lazar AJ; Quezado MM; Reilly KM; Stemmer-Rachamimov A; Stewart DR; Viskochil D; Widemann B; Perry A
    Hum Pathol; 2017 Sep; 67():1-10. PubMed ID: 28551330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
    Friedrich RE; Nörnberg LKN; Hagel C
    Anticancer Res; 2022 May; 42(5):2327-2340. PubMed ID: 35489721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclassification of nerve sheath tumors by gene expression profiling.
    Holtkamp N; Reuss DE; Atallah I; Kuban RJ; Hartmann C; Mautner VF; Frahm S; Friedrich RE; Algermissen B; Pham VA; Prietz S; Rosenbaum T; Estevez-Schwarz L; von Deimling A
    Brain Pathol; 2004 Jul; 14(3):258-64. PubMed ID: 15446580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
    Higham CS; Dombi E; Rogiers A; Bhaumik S; Pans S; Connor SEJ; Miettinen M; Sciot R; Tirabosco R; Brems H; Baldwin A; Legius E; Widemann BC; Ferner RE
    Neuro Oncol; 2018 May; 20(6):818-825. PubMed ID: 29409029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.